Edition:
United States

AstraZeneca PLC (AZN.N)

AZN.N on New York Stock Exchange

34.39USD
4:02pm EDT
Change (% chg)

$-0.23 (-0.66%)
Prev Close
$34.62
Open
$34.59
Day's High
$34.71
Day's Low
$34.36
Volume
476,755
Avg. Vol
795,215
52-wk High
$35.60
52-wk Low
$25.56

Chart for

About

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in... (more)

Overall

Beta: 0.73
Market Cap(Mil.): $85,976.55
Shares Outstanding(Mil.): 2,531.83
Dividend: 0.45
Yield (%): 4.04

Financials

  Industry Sector
P/E (TTM): -- 31.71 16.52
EPS (TTM): -- -- --
ROI: -- 14.89 11.32
ROE: -- 16.15 15.18

BRIEF-US FDA approves new once-weekly BYDUREON® BCise™ injectable medicine for patients with Type-2 diabetes

* US FDA approves new easy-to-use, once-weekly BYDUREON® BCise™ injectable medicine for patients with Type-2 diabetes

8:29am EDT

AstraZeneca among backers as Swiss cancer biotech raises $200 million

LONDON An unlisted Swiss biotech company focused on developing "armed antibodies" to fight cancer has raised $200 million in a funding round backed by AstraZeneca and other private backers.

7:56am EDT

AstraZeneca among backers as Swiss cancer biotech raises $200 mln

LONDON, Oct 23 An unlisted Swiss biotech company focused on developing "armed antibodies" to fight cancer has raised $200 million in a funding round backed by AstraZeneca and other private backers.

7:51am EDT

BRIEF-AstraZeneca and Merck advance LYNPARZA in Japan with a second regulatory submission

* AstraZeneca and Merck rapidly advance LYNPARZA (olaparib) in Japan with a second regulatory submission

7:05am EDT

BRIEF-AstraZeneca and Merck submit application for breast cancer drug in Japan

* ‍ASTRAZENECA AND MSD RAPIDLY ADVANCE LYNPARZA IN JAPAN WITH A SECOND REGULATORY SUBMISSION​

2:28am EDT

BRIEF-AstraZeneca gains FDA backing for Bydureon BCise

* ‍US FDA approves new easy-to-use, once-weekly Bydureon BCise injectable medicine for patients with type-2 diabetes​

2:17am EDT

BRIEF-Roivant Sciences partners with AstraZeneca for drug development

* Roivant Sciences says entered into a development partnership with AstraZeneca for a deprioritized investigational drug in an undisclosed indication​

Oct 19 2017

BRIEF-Fibrogen announces acceptance by china FDA of roxadustat NDA for treatment of anemia associated with dialysis and non-dialysis kidney disease

* Fibrogen announces acceptance by china FDA of roxadustat new drug application (NDA) for treatment of anemia associated with dialysis and non-dialysis chronic kidney disease (CKD)

Oct 18 2017

Astra and Merck win speedy review for Lynparza in breast cancer

LONDON U.S. regulators have granted a priority review to AstraZeneca's ovarian cancer drug Lynparza as a treatment for breast cancer, putting it on track for potential approval in the new disease area during the first quarter of 2018.

Oct 18 2017

Astra and Merck win speedy review for Lynparza in breast cancer

LONDON, Oct 18 U.S. regulators have granted a priority review to AstraZeneca's ovarian cancer drug Lynparza as a treatment for breast cancer, putting it on track for potential approval in the new disease area during the first quarter of 2018.

Oct 18 2017

Competitors

Earnings vs. Estimates